BlueStone Venture Partners

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

Elucid is a Boston-based biotechnology and medical technology company dedicated to enhancing cardiovascular diagnostic imaging through machine learning. The company has developed ElucidVivo, the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography scan, aiding in the assessment of heart attack and stroke risks as well as informing treatment decisions. Elucid's technology enables objective quantification of arterial plaque extent and stability, providing a cost-effective and non-invasive means of capturing essential patient health information. In addition to its proprietary software, Elucid collaborates with pharmaceutical companies, healthcare providers, and research organizations to offer quantitative image analysis services, ultimately aiming to improve patient outcomes in cardiovascular care.

Akadeum Life Sciences, Inc. is a life sciences company based in Ann Arbor, Michigan, specializing in the manufacturing of microbubble cell separation products. Founded in 2014, the company develops bioseparation products that utilize microscopic microbubbles to efficiently capture and isolate target cells from biological samples. Their offerings include T cell and B cell isolation kits for both human and mouse cells, as well as depletion microbubbles for red blood cell separation. Akadeum's products streamline the process of removing specific cells, such as bacteria or viruses, from liquid samples, thereby enhancing the efficiency of downstream testing and analysis. The company also collaborates with strategic partners, including Agilent Technologies, to further advance its innovative solutions in cell separation. Akadeum Life Sciences sells its products online, aiming to improve cell-based research and diagnostics in the life sciences sector.

Elucid is a Boston-based biotechnology and medical technology company dedicated to enhancing cardiovascular diagnostic imaging through machine learning. The company has developed ElucidVivo, the first FDA-cleared software that evaluates plaque vulnerability from a single computed tomography angiography scan, aiding in the assessment of heart attack and stroke risks as well as informing treatment decisions. Elucid's technology enables objective quantification of arterial plaque extent and stability, providing a cost-effective and non-invasive means of capturing essential patient health information. In addition to its proprietary software, Elucid collaborates with pharmaceutical companies, healthcare providers, and research organizations to offer quantitative image analysis services, ultimately aiming to improve patient outcomes in cardiovascular care.

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

Pyx Health, Inc., established in 2017 and headquartered in Tucson, Arizona, specializes in developing a mobile solution that connects with individuals outside traditional healthcare settings to reduce loneliness and social isolation. The company's flagship product, Pyx Health, combines artificial intelligence and human interventions to provide critical and timely support, addressing social determinants of health. Central to this platform is Pyxir, an endearing chatbot personality that accompanies users throughout their healthcare journey, fostering trusted companionship and promoting healthy interaction within the app.

Paradigm Diagnostics specializes in advanced diagnostics technology for personalized cancer treatment. Using Next-Gen Sequencing and other biomarker analysis methods, the company provides detailed information about a patient's genomic and proteomic landscape, identifying specific characteristics of their tumor. This data is used to tailor treatment plans by matching potential therapies to the unique profile of each patient's cancer, thereby enhancing the effectiveness of clinical trials and improving outcomes for cancer patients.

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

BroadSpot Imaging Corporation focuses on developing diagnostic medical devices for eye care, specifically in the area of retinal imaging. The company employs advanced imaging technologies and compact, cloud-connected electronics to create cost-effective handheld instruments that replace traditional bulky and expensive diagnostic tools. By integrating AI and machine learning applications, BroadSpot Imaging aims to enhance the efficiency and accessibility of eye care services. Their innovations are designed to meet the growing demand for high-quality diagnostics, particularly as the population ages, allowing eye care professionals to serve more patients effectively and affordably across various medical settings.